139320 - GP-OSMOTIC STUDY
The research activity is focused on supporting GPs and their patients with type 2 diabetes (T2D) who have out of target HbA1c land are on at least 2 non-insulin hypoglycaemic agents and/or insulin, to improve glycaemic outcomes through timely treatment intensification.
The study tests the effectiveness of retrospective continuous glucose monitoring (rCGM) as an adjunct to HbA1c measurements, to help GP and patient make rational choices about treatment changes. GPs will be trained in the use of rCGM and will then help identify eligible patients who will be invited to participate. Participating patient will randomised to either wear the rCGM device every three months as a part of their diabetes care, or to the control/observation group, where they will continue as usual with their diabetes care. The primary outcome of interest is change in HbA1c.
GPs will be joining a research study funded by the NHMRC and will reflect on their own data compared to the overall study group.
T2D is a leading cause of disease burden, shortening life by up to 5 years and costing $14 billion annually. Treating hyperglycaemia is important in reducing the downstream complications and mortality. Glycaemic control is usually assessed using HbA1c and the general target in Australia is 53mmol/mol (7%). For Australians with T2D, the majority of clinical care is based in general practice where evidence-based clinical care can help people achieve glycaemic targets yet most people with T2D have an HbA1c out of target.
rCGM is a form of structured monitoring of glucose levels. While the effectiveness of random blood glucose monitoring is debated, structured monitoring which can provide new insights into glucose levels and patterns, complementary to and beyond that provided by HbA1c alone. The rationale for the study is that this will empower and motivate people with T2D and their general practitioners to intensify management and make appropriate therapeutic changes.